

PHARMACY POLICY STATEMENT

Marketplace

DRUG NAME	Cinqair (reslizumab)
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Cinqair, approved by the FDA in 2016, is an interleukin-5 (IL-5) antagonist monoclonal antibody indicated for add-on maintenance treatment of severe asthma with an eosinophilic phenotype.

Cinqair (reslizumab) will be considered for coverage when the following criteria are met:

Severe Asthma

For **initial** authorization:

1. Member is at least 18 years of age; AND
- 2.

